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Abstract
NAFLD is the most common chronic liver disease, frequently associated with diabetes. Both of these insulin
resistant states have increased cardiovascular risk factors associated, and a prevalent cause of mortality in these
diseases. Microvesicles are heterogonously sized, phospholipid rich spheres released by cells upon activation and
apoptosis. Evidence is continuing to accumulate of microvesicles being not only markers of disease severity but as
also having a functional role in the pathophysiology of disease progression.
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What are Microvesicles?
Microvesicles are shed from the plasma membrane of almost all
human cells upon activation and apoptosis (Figure 1).
Figure 1: Microvesicles in the blood stream. Microvesicles are
released from activated cells within the vasculature but also from
distant organs. Each microvesicle carries membrane proteins from
the parent cell, allowing identification of the original cell type
(represented by different colours). Some carry nuclear material.
Microvesicles may interact with each other, with different types of
microvesicles or with cells.
A number of stimuli are able to initiate microvesicle release, which
is generally associated with an increase in the cell's intracellular Ca2+
concentration. This increase in Ca2+ is thought to modulate enzymes
involved in the rearrangement of membrane phospholipids
(scramblases, floppases, and flippases) resulting in Ca2+ dependent
proteolysis of the membrane cytoskeleton to release microvesicles.
Microvesicles therefore express the surface proteins of their parent cell
membrane, as well as containing intracellular proteins and/or genetic
material. Microvesicles can be found in a wide range of body fluids
including, blood, urine, saliva, cerebrospinal fluid and amniotic fluid.
Microvesicles are identified predominantly by phosphatidylserine (PS)
exposure and/or their diameter, which ranges from 100-1000 nm.
Microvesicles have been implicated in a number of processes
including angiogenesis, haemostasis, inflammation, cancer
progression and more [1-5]. Due to their size, surface protein
expression and intracellular cargo, microvesicles hold the potential to
be very interesting biomarkers, with fluctuation in microvesicle
numbers and subsets seen in smokers, pregnancy, exercise, obesity,
cancer, autoimmune disease, blood disorders, cardiovascular disease,
infectious disease, and many more (reviewed by Barteneva et al.) [6].
Microvesicles are released in everyone regardless of disease state,
and their numbers reflect the balance between production and
clearance. This basal level of microvesicles may be up- or down-
regulated depending on the situation. Microvesicles have been seen to
vary between individuals by as much as 300,000 fold [7]. As well as
considering changes in microvesicle counts, disease may change
phenotypes and intracellular cargo too. This is likely to be important
when considering the utility of MVs as biomarkers. The half-life of
microvesicles is considered somewhat variable depending on factors
such as size, lipid composition and surface protein expression [8,9].
The half-life of platelet MVs in humans has currently been estimated
at less than 6 hours [8]. Little data currently exists for the clearance of
microvesicles derived from other sources. However, since one of the
main mechanisms in microvesicle clearance is mediated by lactadherin
binding, via phosphatidylserine on the microvesicle surface, to
macrophages, it should not drastically differ from platelets
microvesicles in theory.
Since their identification in 1967, using electron microscopy, our
understanding of microvesicle function has made slow progress,
particularly due to the lack of accuracy of analytical techniques at the
submicron size range. Today, a few options exist for quantification of
microvesicle populations including nanoparticle tracking analysis and
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resistive pulse sensing. The most commonly used technique however is
flow cytometry. As the flow cytometry field has developed to provide
more accurate information for cell analysis, it has inadvertently
provided increased accuracy at a submicron level, with modern high-
end cytometers now capable of analysing a large proportion of the
microvesicle population. Flow cytometry also currently holds the edge
over other techniques where phenotypic analysis is concerned, as a
number of fluorescent labels can simultaneously be analysed per
microvesicle.
Platelet MVs are the most abundant MVs, thought to account for
around 90% of circulating MVs, endothelial, granulocyte and
monocyte are then the next most common [10,11]. These MVs levels
are modulated however depending on the disease and many previous
quantification methods have relied on Annexin V binding, which has
shown inconsistency in binding between protocols and the type of cell
stimulation [12,13]. There is still a need for better development of a
general MV marker, as well as applying cell-specific markers (Table
1) to identify where the microvesicles have originated.
Obesity, Diabetes and NAFLD
Insulin-resistant states such as obesity, type 2 diabetes mellitus
(T2DM) and non-alcoholic fatty liver disease (NAFLD) have all been
associated with variation in microvesicle subsets, when compared to
healthy controls. Those with central obesity are at increased risk of
developing insulin resistance, increasing the risk of developing T2DM
or NAFLD. Those with T2DM are thought to be more susceptible to
developing a more severe form of NAFLD.
Although each of these conditions can exist independently of one
another, it appears they are interconnected through insulin resistance.
All are associated with multi-organ inflammation, including the
vasculature, immune cells and platelets, potentially altering
microvesicle production and consequently the impact of microvesicles
on cellular behaviour (Figure 2). This is reflected in the microvesicle
studies that have been conducted to date, using traditional markers,
which show increases in microvesicle numbers derived from the
endothelial cells, white blood cells and platelets (Table 1). T2DM is by
far the most studied disease, concerning microvesicles, when
compared to obesity and NAFLD; studies identifying the involvement
of microvesicles with NAFLD to date are particularly lacking.
The main cause of mortality in people with T2DM is cardiovascular
disease, and microvesicles released by damaged endothelial cells
represent an ideal candidate biomarker for assessing the risk of
cardiovascular, as well as microvascular, disease burden in patients
with T2DM. Endothelial microvesicles are generally raised; along with
platelet microvesicles in patients with T2DM (Table 1).
Platelet metabolism in T2DM is altered and thought to contribute
to the atherothrombotic complications associated with the disease
[14]. Studies investigating platelet-derived microvesicle markers have
fairly consistently shown increases in T2DM patients when compared
with healthy individuals (Table 1). This increase in platelet
microvesicles could partly account for the hypercoagulable state of the
patients, as platelet microvesicles carry procoagulant molecules.
Increased microvesicles expressing CD142 (tissue factor) is commonly
seen in T2DM patients (Table 1). CD142 is an initiator of coagulation
in vivo, and is predominantly expressed on monocytes; with
expression also found on platelets and eosinophils [15-17]. In the
presence of phosphatidylserine, CD142/factor VII complex activity has
been shown to have a 16 million fold increase in activity [18]. It is
thought that monocyte/macrophage microvesicles bearing CD142
bind to platelets through P-selectin glycoprotein ligand 1 (PSGL-1),
transferring proteins and lipids to the platelet membrane [19]. A
functional study has also shown that PSGL-1 is required for
CD142+microvesicle accumulation in thrombus formation through
CD62P binding in platelets [20]. While convincing, it has also been
shown that CD142+ is not detected within the haemostatic plug at the
site of mice skin wounds, and it is therefore unclear whether CD142
and CD142+microvesicles have a role in haemostasis [21]. Further
studies into the significance of increased microvesicle-bound CD142
in metabolic diseases, and the functional role it plays, are needed.
Figure 2: Potential relationships between microvesicles and insulin
resistance, obesity, T2DM and NAFLD. Microvesicles produced
upon cell activation and apoptosis may alter cellular behaviour in
an autocrine or paracrine fashion, to cause changes that favour the
development of conditions such as T2DM and NAFLD. Examples
of putative microvesicle actions are given. Equally, obesity, insulin
resistance, T2DM and NAFLD may influence the production and
behaviour of microvesicles.
T2DM is associated with a number of other co-morbidities
including kidney disease, retinopathy and neuropathy. Various
publications suggest changes in endothelial, platelet and leukocyte
microvesicle counts during nepthropathy but there is little published
on microvesicle released from kidney-specific cells, or cells related to
the other main pathogenic processes in T2DM. This lack of knowledge
may offer new potential routes to explore in the future.
Many studies to date have used traditional cell markers, using only
a single cell marker to enumerate all microvesicles derived from that
cell e.g. CD42 enumerating all platelet-microvesicles. It is however
increasingly apparent that microvesicles have varying phenotypes, as
do cells, and this phenotype is altered depending upon the stimulant of
the parent cell to produce the microvesicle [22-25]. Fitting the full
repertoire of parent cell membrane surface markers is also unlikely
due to the limited surface area of microvesicles and the area of plasma
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membrane they are shed from. Phenotyping of microvesicles is
therefore becoming more common but has been overlooked in many
of the conducted metabolic studies, which may be failing to observe
the functional and translational significance of the increased numbers
of microvesicles found in these diseases.
Potential microvesicle biomarkers for the future
There are a number of molecules carried on microvesicles that may
prove to be good biologically relevant biomarkers for diabetes and
NAFLD. These include CD36 and Vanin-1, and are discussed in more
detail below.
CD36: The trans-membrane protein fatty acid translocase (FAT/
CD36) is multifunctional, having effects in lipid metabolism,
angiogenesis, atherosclerosis and inflammation. Ligands for CD36
include lipoproteins (HDL, LDL, VLDL, oxidised LDL), long chain
fatty acids, and thrombospondin-1 [26-29]. It has a broad expression
that includes the endothelium, skeletal muscle, dendritic cells,
platelets, monocytes/macrophages, and megakaryocytes [30], which
are all are capable of microvesicle shedding. In 2006, a cell-free form of
CD36 was identified and named soluble CD36 (sCD36). This has since
been associated with atherosclerosis, insulin resistance severity, risk of
T2DM, and liver fat [31-33].
Disease Procoagulant Marker
Microvesicle markers
Author
(↑ increase, ↓ decrease, Ξ maintained)
T2DM Annexin V ↑ CD31+/CD42-, CD31+/CD42+, CD51, CD45, ΞCD62e Feng et al. [60,61]
 Annexin V ↑ total microvesicles CD142, CD66e, CD61 Diamant et al. [62]
 N/A ↑ CD62P, CD63 Shouzu et al. [62]
 N/A ↑ CD62P, CD63, CD14 Ogata et al. [63,64]
 N/A ↑ CD31, CD105, CD106 Tramontano et al. [65]
 N/A ↑ CD42 Nomura et al. [66]
 Annexin V ↑ CD62P, GPIX, CD63, PAC-1, CD14, Nomura et al. [51,67]
 N/A ↑ CD144, ΞCD41 Bernard et al. [68]
 N/A ↑ CD42a/CD42b Nomura et al. [54]
 N/A ↑ CD42b Koga et al. [69]
 Annexin V ↑ CD45, CD66b, CD14 Sabatier et al. [70]
 N/A ↑ CD62P, CD40 Tan et al. [71]
 Annexin V ↑ CD31+/CD42b-, CD31+/AnV+ Jung et al. [72]
 Annexin V ↑ CD42a/42b Nomura [73]
 Annexin V ↑ CD144, CD41, CD62P Tsimerman et al. [74]
 Annexin V ↑ CD142 Sommeijer et al. [75]
NAFLD Annexin V ↑ CD14, ↓ CD41, CD15 Kornek et al. [76]
Obesity Annexin V ↑ Total microvesicles Goichot et al. [77]
 Annexin V ↑ CD31, CD42b Esposito et al. [78]
 N/A ↑ CD144 Gunduz et al. [79]
 Annexin V ↑ Total microvesicles, ↑ CD41+, CD31+/CD41- Stephanian et al. [80]
 N/A ↑ CD41+ Murakami et al. [81]
Platelets Markers – CD41, CD42, CD31, CD61, CD62P
Endothelial Markers – CD144, CD105, CD106, CD31, CD61, CD62P
Leukocyte Markers – CD14, CD15
Macrophage/Monocyte – CD14, CD15, CD105
General Markers – Annexin V, CD63
Table 1: Microvesicle markers relating to cell identification and procoagulant status when compared with healthy individuals.
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In 2011, it was suggested that sCD36 is in fact associated with
microvesicles in the human plasma of healthy individuals, and is not a
cleaved, soluble protein. The study showed sCD36 was particularly
associated with platelet-derived microvesicles, as well as leukocyte-
derived and endothelial-derived [34]. These results coincide with the
finding that PMICROVESICLEs are elevated in patients with type 2
diabetes (Table 1), along with platelet CD36 activation through
lipoproteins, which are also elevated in insulin-resistant states [35-37].
Vanin-1: The imbalance of triglyceride acquisition and removal
leads to the range of disorders in NAFLD. NAFLD is often described
in four stages starting with simple steatosis, leading on to non-
alcoholic steatohepatitis (NASH), fibrosis and finally cirrhosis. At a
cellular level this is characterised by intracytoplasmic triglyceride-
containing lipid droplet accumulation in hepatocytes, which can be
self-limiting, or progress to hepatocyte ballooning and cell death, with
inflammation and/or collagen deposition (fibrosis). From this point
hepatocytes are replaced with scar tissue, which consists mainly of
collagen I [38].
High-fat diets are capable of causing NAFLD. Recently a novel
player in the pathogenesis of NAFLD has been suggested in the form
of vanin-1. Vanin (also known as panetetheinase) is an enzyme found
in the metabolic pathway of co-enzyme A, and has three isoforms in
humans (Vanin-1,2,3) [39]. In humans, Vanin-1 is expressed in the
spleen, small intestine, peripheral blood leukocytes and liver. Other
forms of vanin also exist (Vanin-2 and 3) and are expressed
throughout the body. Vanin hydrolyses pantetheine to form
pentethenic acid (Vitamin B5) and cysteamine which is a potent
antioxidant. Currently the product of vanin-1 activity, cysteamine, is
undergoing clinical trials in NAFLD patients. Cysteamine has been
hypothesised to increase reactive oxygen species (ROS) scavenging and
glutathione production, thereby improving alanine transaminase
(ALT) and aspartate aminotransferase (AST), as well as, inhibiting
transgluatminase activity possibly decreasing fibrin crosslinking and
therefore inhibiting fibrosis [40].
In vitro studies have shown vanin-1 to be upregulated preceding
lipid accumulation and show vanin-1 to be differentially mediated by a
number of free fatty acids [41]. Further studies have identified Vanin-1
as an important activator in hepatic gluconeogenesis, having been
shown to be involved in the development of hyperglycaemia through
increased gluconeogenic gene expression and hepatic glucose out, in
loss- and gain-of-function studies [42]. These studies showed
transcription to be activated by peroxisome proliferator-activated
receptor γ coactivator 1α along with hepatocyte nuclear factor 4α.
Separate studies have also shown the regulation of vanin-1 by
PPARα to be extremely sensitive, and also identify vanin-1 to be a
regulator of hepatic triglyceride levels. Moreover serum vanin-1 has
been put forward as a reliable indicator of PPARα activity in the liver
[43,44].
Interestingly, microvesicle bound vanin-1 has been implicated in
the promotion of angiogenesis during steatohepatitis, specifically on
hepatocyte- microvesicles [45]. Hepatocyte-microvesicles isolated
from medium conditioned by murine hepatocytes, as well as a human
hepatocyte cell line that had been exposed to saturated free fatty acids
and were applied to endothelial cell lines. It was found that the
hepatocyte-microvesicles induced migration and tube formation,
required for angiogenesis, whilst mediums without hepatocyte-
microvesicles, either due to inhibition of formation (through caspase 3
inhibitor) or by ultracentrifugation, lacked proangiogenic activity.
These processes were induced through hepatocyte-microvesicle
internalisation, this however required hepatocyte-microvesicle vanin-1
expression, which was abundantly expressed on the hepatocyte-
microvesicle. Measurement of hepatocyte-microvesicle bound vanin 1
could therefore act as a biomarker in the progression of NAFLD.
In studies using non-cell specific techniques such as microarrays
and western blots, Vanin-1 has been suggested as a biomarker of
kidney damage in the rat model of type 1 diabetic nephropathy using
urine; medium microvesicles are commonly found in [46]. Another
study analysing blood samples showed Vanin-1 as a possible
discriminator, along with MMP9, in the diagnosis of pancreatic
cancer–associated diabetes from type 2 diabetes [47]. Studies
specifically targeting cells and/or microvesicles in these mediums are
therefore required and will shed light on its source.
Effect of metabolic disease medications on microvesicles
Insulin resistant patients can be prescribed numerous medications
for insulin resistance itself and also for cardiovascular protection.
Studies investigating the effects of these medications in insulin
resistant patients further demonstrate the use of microvesicles as
diagnostic markers of disease severity.
Dihydropyridine Ca2+ antagonists, nifedipine and benedipine have
been investigated in normotensive and hypertensive patients with and
without T2DM [48,49]. Platelet- and monocyte-microvesicles were
highest in the hypertensive T2DM, followed by T2DM normotensive,
hypertensive and normotensive, respectively. Following 3 and 6
months of treatment, platelet-, monocyte- and endothelial-
microvesicles were all significantly reduced in the T2DM patients, with
no changes seen in non-diabetic patients. In the benedipine study,
looking at monocyte- and endothelial-microvesicles, T2DM patients
initially had higher numbers of microvesicles than those without
T2DM. All microvesicles levels decreased following the
dyhydropyridine treatment in T2DM patients. Of the healthy controls
treated, only those with anti-oxLDL antibody <8.4 AcU/mL showed
significant decrease in microvesicles, those >8.4AcU/mL did not.
Thiazolidinediones: a randomised, double-blind, comparator-
controlled study comparing the effects of thiazolidinediones,
ploglitazone and metformin, on EMICROVESICLEs in patients with
newly diagnosed T2DM, showed ploglitazone significantly decreased
EMICROVESICLEs, with metformin showing no significant
difference in microvesicle levels. It is worth noting that endothelial
microvesicles were identified as CD31+/CD42-, it is likely a portion of
endothelial microvesicles were CD31+/CD42-/CD41+ and therefore
platelet microvesicles.
Statins: Patients with insulin-resistant diseases are commonly
prescribed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (also termed statins), which reduce the likelihood
of cardiovascular complications. A study investigating the effects of
pravastatin on T2DM patients using Annexin V, CD4, CD8, CD14,
CD20, CD62e, glycol-A, CD66b markers, showed no significant
difference in the number of microvesicles. These microvesicles
markers include T cells, B cells, monocyte/macrophages, granulocytes
and endothelial cells. Platelet microvesicles did not show any
significant change in CD142, they did however show a decrease in
expression levels of CD61. This study shows that the likely inhibition
of GPIIIa on platelets had a knock on effect to the type of platelet
microvesicles that were produced, adding weight to the microvesicles
composition being influenced by the type of activation their parent cell
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receives. An in vitro study looking at the effect of simvastatin on
endothelial microvesicles has shown increased endothelial
microvesicle numbers which is thought to be mediated by inhibiting
prenylation via a caspase 8-dependent mechanism [50]. In vivo studies
looking at microvesicles have shown simvastatin used in combination
with losartan significantly reduced monocyte-, platelet- and
endothelial-microvesicles numbers in combination, when compared to
losartan alone [51,52].
Sulphonylureas: Glibenclamide, is a general ATP-binding cassette
(ABC) transporter inhibitor used to stimulate insulin secretion of
pancreatic β-cells. A study into its effects on monocytes has shown
that glibenclamide caused a reduction in the procoagulant activity of
cells, decreasing the expression of CD142 and decreasing the number
of microvesicles [53].
Alpha-glucoside inhibitors: These prevent the digestion of
carbohydrates. Both miglitol and acarbose, have had their effects
studied on T2DM patient platelet microvesicles, with both showing
significant decreases after 3 months of therapy [54,55].
Fish oils: Eicosapentaenoic acid (EPA) is an omega-3 fatty currently
being investigated as a treatment in NAFLD and T2DM. Studies
investigating EPAs effects on hyperlipidemic volunteers with diabetes
revealed significant decreases in endothelial microvesicles following 6
months of treatment. Non-diabetic patients however, showed no
change in endothelial microvesicles concentrations [56-59].
Conclusion
Whilst it is clear that microvesicles are implicated in numerous
aspects of metabolic diseases and hold the potential for use as
biomarkers, it is also clear that many routinely prescribed medications,
particularly for T2DM, decrease microvesicles in the patients but not
healthy controls. More research is required using phenotypic analysis
of microvesicle subsets, along with functional studies to determine
whether increases in microvesicles and/or their markers are having
positive or negative effects in these diseases. Ultimately this will also
provide information on whether MVs can be used as specific stand-
alone diagnostic markers for the pathogenesis of certain diseases.
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